

human tissues where the nucleic acid molecules in column 3 are predominantly expressed. Of particular note, SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:4 are expressed in reproductive tissues, SEQ ID NO:2 is expressed in hematopoietic/immune tissues, and SEQ ID NO:5 is expressed in liver tissue.

REMARKS

Justification for the amendments is as follows. The specification has been amended in the paragraph beginning at page 8, line 16. Support for these amendments are found in Table 1 which correctly identified the SEQ ID NOs and the columns. No new matter is added by any of these amendments. Applicants respectfully request entry of the present amendments.

Restriction Requirement

In the Restriction Requirement, the Examiner requested Applicants to elect one of the following inventions:

| | | |
|------------|-----------------------------|---|
| Group I | Claims 1-2 | drawn to nucleic acid molecules |
| Group II | Claims 3-6 | drawn to a method of using nucleic acid to screen a library |
| Group III | Claims 7-8 | drawn to ligand that modulates the activity of a nucleic acid |
| Group IV | Claims 9-10 | drawn to a method of using nucleic acids to purify a ligand |
| Group V | Claims 11-12 | drawn to a method for diagnosing a disorder |
| Group VI | Claims 13-14 | drawn to a method for detecting and diagnosing effect of a compound on expression level of nucleic acid molecules |
| Group VII | Claims 15-19 | drawn to proteins |
| Group VIII | Claims 20-21 | drawn to a method of using protein to screen a library |
| Group IX | Claim 22 | drawn to ligand that modulates the activity of a protein |
| Group X | Claim 23 | drawn to a method of using protein to purify a ligand |
| Group XI | Claims 24, 26-27, 29, 36-37 | drawn to an antibody which specifically binds to the protein |
| Group XII | Claim 25 | drawn to a diagnostic test for a condition or a disease using an antibody |

Group XIII Claims 2&, 30 drawn to a method of diagnosing a condition or disease using an antibody


Applicants hereby elect, with traverse, to prosecute Group VII, which includes Claims 15-19 and is drawn to proteins. Applicants point out that claims 20, 21, and 23 of Groups VIII and X represent process claims that depend from and are of the same scope as the product claims of Group VII from which they depend, and could therefore be examined together with the product without undue burden. The Examiner stated that further group restriction is required for Group VIII because claims 20 and 21 comprise a plurality of disclosed patentably methods using patentably distinct libraries of molecules or compounds. Applicants respectfully point out that recited libraries of molecules or compounds are not the subject of patentability in these claims and because claims 20 and 21 of Group VIII are process claims and not composition of matter claims.

In the event that the Examiner determines that the Restriction Requirement should be maintained, Applicants reserve the right to prosecute the non-elected claims in subsequent divisional applications.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108.


Respectfully submitted,
INCYTE GENOMICS, INC.

Date: May 29, 2002



David G. Streeter, Ph.D.
Reg. No. 43,168
Direct Dial Telephone: (650) 845-5741

Date: 20 May, 2002



Yu-Mei Eureka Wang, Ph.D.
Reg. No. 50,510
Direct Dial Telephone: (650) 621-8740

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

**VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE SPECIFICATION:**

Paragraph(s) beginning at line 16 of page 8 has been amended as follows:

Table 1 shows the nucleic acid molecules present in benzo(a)pyrene-treated rat liver and absent in untreated rat liver, SEQ ID NOs:9[8]-13, and their human homologs, SEQ ID NOs:1-5. Columns 1 and 2 list the SEQ ID NO and Incyte ID number, respectively, for each rat nucleic acid molecule, SEQ ID NOs:9[8]-13, present in benzo(a)pyrene-treated liver and absent in untreated liver. These nucleic acid molecules were used to identify the human nucleic acid molecules shown in columns 3 and 4. Columns 3 and 4 list the SEQ ID NO and Incyte ID number, respectively, for each human nucleic acid molecule. Column 5 shows exemplary unique fragments of SEQ ID NOs:1-5. Such fragments of SEQ ID NOs:1-5 are useful in hybridization or amplification technologies to identify changes in expression pattern of the same or similar sequences. Column 6[5] shows the sequence identity between the rat nucleic acid molecule in column 1 and the corresponding human nucleic acid molecule in column 3. Column 7[6] identifies the human tissues where the nucleic acid molecules in column 3 are predominantly expressed. Of particular note, SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:4 are expressed in reproductive tissues, SEQ ID NO:2[4] is expressed in hematopoietic/immune tissues, and SEQ ID NO:5 is expressed in liver tissue.